Cytek Biosciences, Inc.
Cytek Biosciences, Inc. (CTKB) Revenue
Annual & quarterly revenue history · segment & region breakdown
CTKB · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsCytek Biosciences, Inc. trailing twelve-month (TTM) revenue is $0.20B, an increase of 0.52% year-over-year from $0.20B in FY2025.
Revenue trend
2025 – 2019 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.20B | +$0.00B | +0.52% |
| 2024-12-31 | $0.20B | +$0.01B | +3.85% |
| 2023-12-31 | $0.19B | +$0.03B | +17.67% |
| 2022-12-31 | $0.16B | +$0.04B | +28.20% |
| 2021-12-31 | $0.13B | +$0.04B | +37.82% |
| 2020-12-31 | $0.09B | +$0.03B | +60.39% |
| 2019-12-31 | $0.06B | — | — |
Compare revenue vs peers
Medical - DevicesCompare CTKB revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Cytek Biosciences, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Cytek Biosciences, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Cytek Biosciences, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
CTKB revenue · 4 questionsCTKB's trailing twelve-month (TTM) revenue is $0.20B. That is an increase of 0.52% year-over-year from $0.20B in FY2025.
▸ Source: FMP · Cytek Biosciences, Inc. SEC filings · GAAP · Cytek Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026